Holen Sie sich die Stockscreener-App
6.92
6.49%
-0.48
Schlusskurs vom Vortag:
$7.40
Offen:
$7.41
24-Stunden-Volumen:
380.49K
Relative Volume:
0.95
Marktkapitalisierung:
$268.64M
Einnahmen:
$5.74M
Nettoeinkommen (Verlust:
$-166.12M
KGV:
-1.731
EPS:
-3.9978
Netto-Cashflow:
$-131.64M
1W Leistung:
-10.36%
1M Leistung:
+15.91%
6M Leistung:
-30.94%
1J Leistung:
+2.37%
1-Tages-Spanne:
$6.73
$7.44
1-Wochen-Bereich:
$6.73
$7.90
52-Wochen-Spanne:
$4.93
$16.45
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Firmenname
Entrada Therapeutics Inc
Sektor
Branche
Telefon
857-305-1825
Adresse
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
6.92 | 268.64M | 5.74M | -166.12M | -131.64M | -3.9978 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-02-11 | Eingeleitet | Guggenheim | Buy |
| 2026-01-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten
Why (TRDA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewir - The National Law Review
Entrada Therapeutics, Inc.(NasdaqGM: TRDA) dropped from Russell 2000 Defensive Index - marketscreener.com
Understanding Momentum Shifts in (TRDA) - Stock Traders Daily
Price to book forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Price to earnings forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Price to sales forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Enterprise value to revenue forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Entrada Therapeutics Inc Actuals & Estimates (NASDAQ:TRDA) - TradingView
TRDA Forecast — Price Target — Prediction for 2027 - TradingView
Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TRDA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Entrada Therapeutics Inc (TRDA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Entrada Therapeutics Inc (TRDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Entrada Therapeutics Inc (TRDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Avoiding Lag: Real-Time Signals in (TRDA) Movement - Stock Traders Daily
Entrada Therapeutics Inc (TRDA) Institutional Confidence - TradingKey
Entrada Therapeutics Inc (TRDA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Entrada Therapeutics Inc (TRDA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Entrada Therapeutics Inc (TRDA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Entrada Therapeutics Inc (TRDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity - Stock Titan
Entrada Therapeutics (TRDA) awards director 19,000 options at $5.97 - Stock Titan
Entrada Therapeutics director granted 19,000 options | TRDA Insider Trading - Stock Titan
Entrada Therapeutics (TRDA) director receives 19,000-share stock option grant - Stock Titan
Entrada Therapeutics (TRDA) director receives grant of 19,000 stock options - Stock Titan
Entrada Therapeutics (TRDA) Gains Ground: Modest Rally Tests Key Resistance LevelsDay Trade Opportunities - newsline.com
Entrada Therapeutics Stockholders Approve Directors and Equity Plans - The Globe and Mail
[8-K] Entrada Therapeutics, Inc. Reports Material Event - Stock Titan
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE) - The Globe and Mail
Entrada Therapeutics Inc. (TRDA) Q1 2026 Earnings: Narrower Loss Surprises, but No Revenue Weighs on SharesROIC Trend Report - newsline.com
Entrada Therapeutics (TRDA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Entrada Therapeutics Inc. (TRDA) Faces Selling Pressure as Shares Dip to $6.20Triple Top - dars.gov.et
Discipline and Rules-Based Execution in TRDA Response - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc.TRDA - PR Newswire
TRDA: Strong safety and early efficacy in DMD trials drive confidence in a growing clinical pipeline - TradingView
Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Safety committee approves higher 10 mg/kg dose for Entrada's Duchenne muscular dystrophy trial - Pluang
Entrada gets clearance to escalate dose in DMD trial By Investing.com - Investing.com South Africa
Entrada gets clearance to escalate dose in DMD trial - Investing.com
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study - The Manila Times
Rare disease trial tests DMD treatment with once-every-six-week dosing - Stock Titan
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Entrada Therapeutics, Inc. (TRDA) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-05-27 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Entrada Therapeutics, Inc. (TRDA) And Encourages Shareholders to Reach Out | NDAQ:TRDA | Press Release - Stockhouse
Behavioral Patterns of TRDA and Institutional Flows - Stock Traders Daily
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Entrada Therapeutics, Inc. (TRDA) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
TRDAEntrada Therapeutics Inc Stock Price and Quote - Finviz
Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutics, Inc. (TRDA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Finanzdaten der Entrada Therapeutics Inc-Aktie (TRDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):